Published in PLoS One on November 28, 2013
The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children. J Virus Erad (2015) 0.82
HIV DNA Vaccine: Stepwise Improvements Make a Difference. Vaccines (Basel) (2014) 0.81
Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. Clin Vaccine Immunol (2015) 0.80
Immunotherapy with an HIV-DNA Vaccine in Children and Adults. Vaccines (Basel) (2014) 0.78
Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection. Hum Vaccin Immunother (2016) 0.75
Adherence to medication. N Engl J Med (2005) 39.77
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol (2009) 2.95
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep (2009) 2.02
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Res (1990) 1.76
T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog (2007) 1.70
Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health (2003) 1.68
Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS (2004) 1.49
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol (2011) 1.19
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol (2010) 1.18
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis (1999) 1.03
Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology (2002) 0.99
Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection. J Immunol (2012) 0.98
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS (2011) 0.98
Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol (2012) 0.95
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol (2012) 0.94
Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine (2005) 0.94
Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS (2011) 0.89
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine (2011) 0.87
Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained. PLoS One (2011) 0.83
The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine (2011) 0.81
Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. AIDS (2007) 0.80
Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. Viral Immunol (2012) 0.79
Plasmid DNA containing multiple CpG motifs triggers a strong immune response to hepatitis B surface antigen when combined with incomplete Freund's adjuvant but not aluminum hydroxide. Mol Med Rep (2012) 0.78
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci U S A (2008) 6.76
NMR structure determination for larger proteins using backbone-only data. Science (2010) 3.00
Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol (2002) 2.77
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr (2011) 2.75
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol (2007) 2.38
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest (2003) 1.92
The high-throughput protein sample production platform of the Northeast Structural Genomics Consortium. J Struct Biol (2010) 1.90
Structural basis for protein antiaggregation activity of the trigger factor chaperone. Science (2014) 1.86
Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A (2009) 1.84
Determination of solution structures of proteins up to 40 kDa using CS-Rosetta with sparse NMR data from deuterated samples. Proc Natl Acad Sci U S A (2012) 1.83
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Preparation of protein samples for NMR structure, function, and small-molecule screening studies. Methods Enzymol (2011) 1.75
Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain (2005) 1.74
The lower limb flexion reflex in humans. Prog Neurobiol (2005) 1.67
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 1.65
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol (2007) 1.63
A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc (2008) 1.60
Congenital coronary artery anomalies angiographic classification revisited. Int J Cardiovasc Imaging (2003) 1.57
Quantum chemical 13C(alpha) chemical shift calculations for protein NMR structure determination, refinement, and validation. Proc Natl Acad Sci U S A (2008) 1.50
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Paternal transmission of symbiotic bacteria in malaria vectors. Curr Biol (2008) 1.44
Asaia, a versatile acetic acid bacterial symbiont, capable of cross-colonizing insects of phylogenetically distant genera and orders. Environ Microbiol (2009) 1.42
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med (2009) 1.40
Role of individual's T-cell immunome in controlling HIV-1 progression. Immunology (2014) 1.39
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon. J Acquir Immune Defic Syndr (2003) 1.38
Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics (2008) 1.38
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog (2010) 1.36
Determination of the structures of symmetric protein oligomers from NMR chemical shifts and residual dipolar couplings. J Am Chem Soc (2011) 1.35
DNA vaccines: recent developments and future possibilities. Hum Gene Ther (2006) 1.33
Gene-based vaccines: recent technical and clinical advances. Trends Mol Med (2006) 1.32
Solution NMR structure of the NlpC/P60 domain of lipoprotein Spr from Escherichia coli: structural evidence for a novel cysteine peptidase catalytic triad. Biochemistry (2008) 1.27
Mosquito-bacteria symbiosis: the case of Anopheles gambiae and Asaia. Microb Ecol (2010) 1.27
Blind testing of routine, fully automated determination of protein structures from NMR data. Structure (2012) 1.23
Delayed larval development in Anopheles mosquitoes deprived of Asaia bacterial symbionts. BMC Microbiol (2012) 1.20
Ten years of descending necrotizing mediastinitis: management of 23 cases. J Oral Maxillofac Surg (2007) 1.19
Comparisons of NMR spectral quality and success in crystallization demonstrate that NMR and X-ray crystallography are complementary methods for small protein structure determination. J Am Chem Soc (2005) 1.19
Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation (2009) 1.19
Vaccine delivery methods using viral vectors. Mol Pharm (2007) 1.17
Molecular evidence for multiple infections as revealed by typing of Asaia bacterial symbionts of four mosquito species. Appl Environ Microbiol (2010) 1.15
Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis (2009) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther (2004) 1.13
A nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS (2006) 1.11
Microgram-scale protein structure determination by NMR. Nat Methods (2007) 1.11
Accurate automated protein NMR structure determination using unassigned NOESY data. J Am Chem Soc (2010) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Effects of diffuse noxious inhibitory controls on temporal summation of the RIII reflex in humans. Pain (2004) 1.08
B-cell subset alterations and correlated factors in HIV-1 infection. AIDS (2013) 1.08
Predictors of nurses' perceptions of barriers to research utilization. J Nurs Manag (2008) 1.07
Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS (2003) 1.07
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J (2013) 1.06
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine (2009) 1.05
Construct optimization for protein NMR structure analysis using amide hydrogen/deuterium exchange mass spectrometry. Proteins (2009) 1.05
Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol (2011) 1.05
Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol (2006) 1.04
Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identification of novel CYBB mutations: an Italian multicenter study. Mol Immunol (2009) 1.03
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther (2007) 1.03
Why do nurses at a university hospital want to quit their jobs? J Nurs Manag (2005) 1.01
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther (2005) 1.01
Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol (2003) 1.00
Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology (2002) 0.99
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol (2013) 0.98
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS (2002) 0.98
Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol (2011) 0.97
Mosquito/microbiota interactions: from complex relationships to biotechnological perspectives. Curr Opin Microbiol (2012) 0.97
Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis (2002) 0.97
Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine (2004) 0.97
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res (2008) 0.97
Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS (2003) 0.97
Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine (2010) 0.96
Ten-year survivorship of the Anatomique Benoist Girard I total hip arthroplasty. J Arthroplasty (2007) 0.96
Interactions between Asaia, Plasmodium and Anopheles: new insights into mosquito symbiosis and implications in malaria symbiotic control. Parasit Vectors (2013) 0.96
Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin Diagn Lab Immunol (2004) 0.96
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96
Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp (2010) 0.96
Immune deficiency caused by impaired expression of nuclear factor-kappaB essential modifier (NEMO) because of a mutation in the 5' untranslated region of the NEMO gene. J Allergy Clin Immunol (2010) 0.96
Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up. Pediatr Infect Dis J (2014) 0.95
Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol (2004) 0.95
Exposure of workers to electromagnetic fields. A review of open questions on exposure assessment techniques. Int J Occup Saf Ergon (2009) 0.94
Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol (2005) 0.94
Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol (2010) 0.94